# EDGAR Filing Document

**Accession Number:** 0001662774
**File Stem:** 0001662774-25-000034
**Filing Date:** 2025-6
**Character Count:** 7674
**Document Hash:** 9e2a25dbbc9ae9712c9f455c0b601b16
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001662774-25-000034.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001662774-25-000034

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quince Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662774
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 901024039
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38890
- **FILM NUMBER:** 251027236

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-910-5717

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cortexyme, Inc.
- **DATE OF NAME CHANGE:** 20160104

?xml version='1.0' encoding='ASCII'? qncx-20250604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

______________________

**FORM 8-K**

______________________

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 4, 2025**

______________________

**QUINCE THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)**

______________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38890** | **90-1024039** |
| **(State or other jurisdiction of**<br>**incorporation)** | **(Commission**<br>**File Number)** | **(IRS. Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **601 Gateway Boulevard , Suite 1250**<br>**South San Francisco, California** | **94080** |
| **(Address of principal executive offices)** | **(Zip Code)** |
| **Registrant's telephone number, including area code: (415) 910-5717** | **Registrant's telephone number, including area code: (415) 910-5717** |

---

**Not Applicable**

**(Former name or former address, if changed since last report.)**

______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, par value $0.001 per share | QNCX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.07&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.** 

The Annual Meeting of Stockholders of Quince Therapeutics, Inc. (the "Company") was held online via live webcast on June 4, 2025 (the "Annual Meeting"). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 31,517,652 shares of common stock, or approximately 71.43% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:

***Proposal One - Election of Directors***

The Company's stockholders approved the election of three Class III directors to the Board of Directors to serve until the 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal. The results of such vote were:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| June Bray | 15,349,744 | 2,109,599 | 14,058,309 |
| Christopher J. Senner | 16,227,725 | 1,231,618 | 14,058,309 |
| Rajiv Patni, M.D. | 16,270,053 | 1,189,290 | 14,058,309 |

---

***Proposal Two - Approval of Amendment to the Certificate of Incorporation to increase the total number of authorized shares of the Company's common stock from 100,000,000 to 250,000,000 shares***

The Company's stockholders approved the amendment to the Company's certificate of incorporation to increase the total number of authorized shares of the Company's common stock from 100,000,000 to 250,000,000 shares. The results of such vote were:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 27,159,134 | 3,776,348 | 582,168 |

---

***Proposal Three - Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split***

The Company's stockholders approved the amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's issued and outstanding common stock at a ratio of one-for-ten with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's board of directors in its sole discretion. The results of such vote were:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 28,083,296 | 3,309,927 | 124,428 |

---

***Proposal Four - Ratification of Selection of Independent Registered Accounting Firm***

The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025. The results of such vote were:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 30,015,571 | 1,274,997 | 227,083 |

---

***Proposal Five - Approval, on an advisory basis, of the compensation of the Company's named executive officers***

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. The results of such vote were:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 16,590,485 | 800,094 | 68,764 | 14,058,309 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **QUINCE THERAPEUTICS, INC.** | **QUINCE THERAPEUTICS, INC.** |
| | By: | /s/ Dirk Thye |
| Date: June 5, 2025 | Name: | Dirk Thye |
|  | Title: | Chief Executive Officer and Chief Medical Officer |

---